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3“Elimu haina mwisho” - proverb
                      Education has no end
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5ABSTRACT
Aim: The overall aim of this thesis was to determine comorbidity, incidence and mortal-
ity in heart failure (HF) in young adults and particularly in peripartum cardiomyopathy 
(PPCM). More specifi c objectives in PPCM patients were to describe the role of concomi-
tant preeclampsia, prognostic factors of symptomatic and left ventricular recovery. Finally 
we also wanted to assess left ventricular and arterial compliance in PPCM patients.
Methods: In paper I we linked mortality data from the Cause-specifi c Death Register 
and discharge diagnoses from the Inpatient Register. In paper II we further linked these 
two registries with the Medical Birth Register. In paper III we reviewed a clinical cohort 
with PPCM and compared prognostic factors associated with early and late symptomatic 
recovery. In paper IV consecutive PPCM patients were compared with healthy controls 
with respect to left ventricular contractile reserve, diastolic function and arterial stiffness.
Results: Paper I: From 1987 to 2006, there were 443 995 HF hospitalisations among 
adults 18–84 years in Sweden. Of these, 3.0% occurred in people aged 18–54 years. An 
almost 50% increase among people aged 18–44 years was seen in contrast to people 
≥45years where incidence peaked in the mid-1990s. Case fatality decreased for all age 
groups, but only up until 2001. Paper II: Countrywide 272 PPCM cases and 1341 controls 
were identifi ed. Mean incidence was 1 in 9191 deliveries. PPCM cases had higher BMI 
(OR) 1.05, were more likely to be of non-OECD country origin OR 1.61, have multifetal 
births OR 2.26 and have a higher prevalence of preeclampsia OR 13.02. From 1987-2006, 
8.1% of cases and 0.4% of controls had died. Preeclampsia was inversely associated with 
mortality. Paper III: 24 cases of PPCM were identifi ed. Mean (SD) LVEF at diagnosis was 
34.7% (10.7). All patients received -blockers and ACE-I/ARB. Review was performed at 
4.8 (2.8) years. Late/non-recovery vs. early recovery was associated with larger LV size at 
diagnosis, P=0.02. Preeclamptic PPCM cases (58.3%), recovered earlier, P=0.001. Paper 
IV: 22 PPCM cases and 15 controls, underwent review 3 years after diagnosis, including 
2-D echo and arterial stiffness assessment at rest and immediately post-exercise.  Blood 
pressure was higher among cases (122/76) than controls (111/67), P=0.01. NT-proBNP 
was elevated in all cases. Increased LV and arterial stiffness was seen in cases compared 
with controls. 
Conclusions: We showed that the incidence of HF among adults <55 years increased while 
mortality decreased between 1987 and 2006. PPCM incidence during the period was 1 in 
9200 deliveries, which is lower than most other studies. Mortality at the end of the study 
period was >20 higher in cases than controls. Preeclampsia was strongly associated with 
PPCM, but inversely associated with mortality. Likewise paper III and IV revealed that 
large LV size and the absence of concomitant preeclampsia was linked to worse prognosis. 
LV and arterial compliance remain reduced 2.7 years after diagnosis. Longer follow-up of 
PPCM patients should be pursued with specifi c attention to diastolic function and reduced 
arterial compliance. Hence the notion of complete PPCM recovery, may need revision.  
Key words: Heart failure, Young adults, Epidemiology, Cardiomyopathy, Peripartum, 
Pregnancy, Preeclampsia, Prognosis, Incidence, Echocardiography, Vascular age
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ACHD   Adult congenital heart disease (grown-up congenital heart  
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AIx   Augmentation index
BMI   Body mass index
BP   Blood pressure
CDR   Cause-Specifi c Death Register
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Heart failure (HF) is a syndrome and not per se a diagnosis. HF has no singular patho-
logical process or etiology. HF is - in keeping with the current ESC guidelines for the 
diagnosis and treatment of acute and chronic HF 2012 - for clinical purposes defi ned 
as: “a syndrome in which patients have typical symptoms (e.g. breathlessness, ankle 
swelling and fatigue) and signs (e.g. elevated jugular venous pressure, pulmonary 
crackles and displaced apex beat) resulting from abnormality in cardiac structure 
and function”.1 HF can be diffi cult to diagnose as many of the symptoms are non-
discriminating and of low diagnostic value, but with the aid of echocardiography and 
natriuretic peptides levels, the diagnosis can still be verifi ed despite a vague or mild 
presentation. HF is numerically a disease of the elderly with a dramatic increase in in-
cidence from the age of 70. Therefore, Sweden which has a relatively old population, 
also has a disproportionately high disease burden - despite declining age-adjusted 
prevalence - amounting to 144 000 persons who have been hospitalised for and living 
with HF in 2007.2 HF is associated with frequent readmissions, and  accounts for the 
highest share of cardiac admissions incurring more healthcare expenditure than any 
other cardiovascular diagnosis.3 Despite improved outcomes in the management of 
coronary heart disease and HF,4 the disease in the elderly still carries a 50% fi ve-year 
mortality, parallel to that of many cancers.5, 6 While studies indicate that HF incidence 
and mortality in Sweden, Scotland and Australia have been decreasing since the early 
1990s,7-9 worldwide HF prevalence is still on the rise as middle and lower income 
countries have entered the era non-communicable diseases.1
Heart failure in young adults
HF among the young is uncommon, but may exert greater impact on active and in-
come-generating individuals with several dependents.1 Most HF data are based on 
older adults, and accordingly, little is known about the aetiology, incidence and trends 
in HF among younger patients.10, 11 While ischemic heart disease and hypertension are 
predominant causes of HF among older patients, the aetiological make-up of HF in 
young adults, according to trial data, is more heterogeneous.12, 13  Causes of HF among 
the young include adult congenital heart disease (ACHD), idiopathic cardiomyopa-
thies, myocarditis or alcohol- or drug-related myocardial lesions.14, 15 Even more dis-
ruptive than HF in young age, is possibly HF during pregnancy, albeit a rare occur-
rence, it constitutes the most common cause of cardiovascular disease in pregnant 
women.16 HF during pregnancy poses particular dangers as symptoms may mimic 
those of physiological pregnancy.17
PPCM – an introduction
The primary focus of this thesis – peripartum cardiomyopathy, constitutes a subset of 
HF in the peripartum period. PPCM is defi ned as pregnancy-associated cardiomyopa-
thy characterised by unexplained new-onset systolic - LVEF <45% - HF during the 
last months of pregnancy or in the months following delivery where no other cause of 
pre-existing HF is found.18 
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The epidemiology of PPCM is largely unknown and the incidence in Asia and Europe 
is uncertain.17 Previous studies have shown varying incidence rates from approxi-
mately 1:1000 in South Africa,19 to 1:2000 to 1:9700 in various sub-populations in 
USA,20-23 and 1:20 000 in Japan.24 Published European clinical data are scarce,17,25,26 but 
largely in agreement with existing US studies27, 28 where high maternal age, multifetal 
pregnancy, diabetes and African descent are known to be associated with PPCM.26, 28-31 
Putative risk factors are advanced maternal age, high parity, multifetal pregnancy, 
sub-Saharan African heritage and preeclampsia22, 24, 32 and more recently anaemia and 
substance abuse.33
Preeclampsia deserves separate attention as it very frequently coexists with PPCM, 
but little is known about its infl uence on the clinical course and symptomatic recovery 
in PPCM.34, 35  Preeclampsia is known to increase therapy resistant hypertension and 
arterial stiffness postpartum.36, 37
The underlying causes of PPCM have not been fully elucidated, but a number of 
hypotheses including infl ammatory processes and genetic predisposition18 have been 
proposed. Increasing evidence now points towards endothelial dysfunction, uncon-
trolled oxidative stress and impaired angiogenesis as main drivers in the pathogen-
esis.38, 39, 40 
Endothelial dysfunction affects vessel stiffness and is known to affect myocardial sys-
tolic and diastolic function and performance,41 including coronary perfusion and car-
diovascular hemodynamics.38 Endothelial dysfunction is also associated with adverse 
outcome in HF,41 and it has been shown that increased arterial stiffness is an added 
independent marker of future cardiovascular adverse outcome.42, 43  It also correlates 
well with global diastolic dysfunction and reduced LV compliance though their exact 
causal relationship remains unclear.44
No data on prognosis for PPCM beyond seven years have been reported.27 Survival 
is known to vary geographically.24, 33, 45, 46 Thus 7-year mortality in one study was re-
ported to be 24% among African American women.47 Identifying independent predic-
tors of mortality has been diffi cult, as the number of reported fatalities remains low. In 
outcome studies, African-American ethnicity, left ventricular end-diastolic diameter 
and low LVEF <25–30% at presentation all have been associated with reduced left 
ventricular recovery or death.21, 46, 47 
Prognosis in terms of LV recovery has mostly been examined with respect to left 
ventricular ejection fraction (LVEF) and LV dimensions, but other parameters of LV 
function such as contractile reserve, longitudinal contractility, and global diastolic 
function are poorly examined in this population.26, 46, 48, 49 Also little is known about the 
long term effects of PPCM on cardiovascular ageing.
PPCM is managed according to the current guidelines for HF,18 but there are no tai-
lored evidence based guidelines for the medical management of PPCM neither at 
presentation, nor during recovery.16
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Echocardiography
Transthoracic echocardiography examination (TTE) is the preferred imaging modal-
ity to assess cardiac function. It relies on ultrasonography and is the golden standard 
for functional non-invasive cardiac evaluation. Several methodologies including, M-
mode, 2-D (Figure 1), Doppler, Tissue Doppler and 2-D strain imaging are available. 
These modalities allow for the measurement of the timing and rate of myocardial 
contractility, determination of cardiac volumes in the different phases of the cardiac 
cycle, assessment of the hemodynamics of cardiac valves, the assessment of myocar-
dial stiffness and velocity, and quantifi cation of myocardial thickening and incursion. 
In HF both systolic and diastolic dysfunction can readily be assessed through TTE 
provided adequate echogenicity is achieved. TTE is crucial in the assessment of LV 
function in HF and PPCM as subnormal LVEF and diastolic dysfunction are signs 
of persistent left ventricular dysfunction calls for continued treatment optimization. 
Further, LVEF <36% should prompt targeted pharmacological treatment.1 LV global 





Figure 1. Transthoracic echocardiographic images of the heart. A: parasternal long-axis view. 
B: Parasternal short-axis view.
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Arterial stiffness
Arterial stiffness or vascular ageing also implies impaired endothelial function and 
is a condition of defi cient vessel compliance. Compliance describes volume change 
per incremental pressure change (C= ∆V/∆P).  Arterial stiffness has increasingly been 
investigated as a sentinel marker of cardiovascular disease and is known to be an 
added independent marker of future adverse outcomes.42, 43 It is also known to affect 
myocardial systolic and diastolic function41, coronary circulation and cardiovascu-
lar hemodynamics.38 Endothelial dysfunction is associated with adverse prognosis in 
HF,41 and increased arterial stiffness is an added independent marker of future cardio-
vascular adverse outcome.42, 43  It also correlates well with global diastolic dysfunction 
and reduced LV compliance though their exact causal relationship remains unclear.44 
Arterial stiffness it is largely assessed through  by pulse wave (PWV) velocity and 
augmentation index (AIx) measurements.
PWV is a known index of compliance in the large collagenous conduit vessels in con-
trast to the muscular resistance vessels of the peripheral vasculature. Increased PWV 
at the aortic level is correlated with arterial ageing and predicts cardiovascular adverse 
events beyond traditional risk factors.51 
AIx measures arterial stiffness and is an index of peripheral vascular tone and resis-
tance at the arteriolar level and thus of endothelial function.52 It is calculated as the 
difference between the direct and refl ected systolic peak pressures, divided by the 
pulse pressure, mmHg (PP); (Prefl ected-Pdirect)/PP x 100). Arteriograph
©, a device used 
to determined arterial stiffness, has been validated against SphygmoCor© - an older 
device - and invasive recordings. Both Arteriograph© and SphygmoCor© were inde-
pendently strongly correlated with invasive recordings.53,54 
Figure 2. The principle of the Arteriograph©. A pressure sensor in the blood pressure cuff records 
the pressure fl uctuations at 35 mmHg above systolic pressure. The time between the two peaks, 
the red ejection peak and the green refl ected peak corresponds to twice the aortic distance. The 
surrogate measure is the distance between the symphysis and the jugular notch. The brachial 
augmentation index is calculated from the difference in height between the two peaks.53
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AIMS
The overall aim of this thesis was to gain more knowledge about HF in young adults 
and particularly PPCM through epidemiological and clinical data collection and tar-
geted cardiovascular examination.
Specifi c objectives
•    Through linking the national Inpatient (IPR) and Cause-Specifi c Death (CDR) 
registries we aimed to investigate age-specifi c national trends in HF in approxi-
mately 440,000 hospital discharges over a period of 20 years concerning:
 incidence
 comorbidity
 one-year case fatality 
•    Through linking population-based data from the Swedish national Medical Birth 
Register (MBR), the IPR, and the CDR to identify a PPCM cohort and primarily 
determine the following:
 incidence of PPCM in Sweden
 patient characteristics
 mortality between 1987 and 2010.
•   In a Swedish clinical cohort of PPCM patients to identify or describe:
 basic patient characteristics
 the hallmarks of PPCM with and without coexisting preeclampsia
 prognostic clinical markers of poor symptomatic recovery
 pharmacological management in these patients.
•     In PPCM cases, compared with age- matched healthy controls who had undergone 
clinical and echocardiographic review, to assess: 
 arterial stiffness
 LV structure  and function
  LV contractile reserve through functional tests at rest and during exercise 
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METHODS
Study populations and design
In paper I we retrospectively looked at all adults younger than 55 years who devel-
oped HF in a period from 1987-2006. Patients were identifi ed through linking data 
from the IPR and CDR using the unique national personal identity number. Paper II 
was a retrospective case-control study where we linked data from the two registers 
mentioned above, with the MBR to identify a subpopulation of young adults with HF, 
but specifi cally women with pregnancy-associated HF or PPCM between 1987 and 
2010. The age- and year of delivery-matched controls were sampled from the MBR. 
Between 1987 and 1996, the International Classifi cation of Diseases Ninth Revision 
(ICD-9) was in use, and thereafter, ICD-10. In paper III and IV we clinically identifi ed 
a cohort of women with PPCM in two western Swedish counties (Halland and Västra 
Götaland) between 2005 and 2013 and did journal, clinical and echocardiographic 
reviews.
Young adults with HF – I
We included all patients aged 18 to 54 years from 1987 to 2006 who had a fi rst-ever 
HF diagnosis code in any position. Secondary HF diagnoses were included because a 
large percentage of younger patients with HF have other primary aetiological diagno-
ses e.g. myocarditis or hypertension. 
PPCM and pregnancy-associated HF in Sweden – II
From 1987–2010, 1 378 544  mothers aged 15–54 years were registered with an ob-
stetric diagnosis of 630–676 (ICD-9) or O00–O99 (ICD-10), of which 11 284 cas-
es received any concurrent diagnosis of the circulatory system: 390–459, 745–747, 
758A, 758G, 759W (ICD-9) or I00–I99, Q20–Q28, Q87.1E, Q87.4, Q90 & Q96 
(ICD-10), within a year of any obstetric diagnosis and delivery. Each case was then 
randomly assigned 5 controls from the MBR matched for maternal age and year of 
delivery, for a total of 56 379 controls. Of the 11 284 cases, 350 had a diagnosis code 
within the pre-specified time range to delivery of −30 days up to +180 days. Because 
our own clinical experience had indicated that a substantial number of women with 
new-onset HF towards the end of pregnancy and in the months following delivery, 
do not receive a PPCM code (674W (ICD-9) or O903 (ICD-10)), but a diagnosis of 
heart failure or cardiomyopathy; we used the following as proxy codes, i.e., cardio-
myopathy 425 (ICD-9), I42, I43 (ICD-10) and/or HF 428A, 428B, 428X (ICD-9) and 
I50 (ICD-10) within 30 days before delivery up to 180 days post-partum. To avoid 
inclusion of other underlying aetiologies, we used the following exclusion codes: any 
diagnosis of cancer 140–208 (ICD-9), C00–C97 (ICD-10); adult congenital heart 
disease (ACHD) 745–747 (ICD-9), Q20–Q28, Q87, Q89 (ICD-10); ischemic heart 
disease (IHD) 410–414 (ICD-9), I20–I25 (ICD-10), or pre-existing HF. Because the 
diagnosis codes used did not have 100% accuracy, and because an HF diagnosis did 
not guarantee idiopathic HF, manual review of the MBR and IPR of these 350 entries 
was performed to validate the diagnosis. In this way, another 78 cases were excluded 
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owing to: the PPCM or HF diagnosis being ambiguous (a 674W code with no other 
indication of HF), previously unidentifi ed pre-existing HF, IHD, ACHD or cancer, 
valvular disease, arrhythmia, pulmonary embolism, septicaemia, and a case of sickle 
cell-induced anaemia (Figure 3).
No obstetric diagnosis within one 
year of an obstetric diagnosis 
n = 1 366 638






• Any pre-existing condition 




Women with an obstetric diagnosis code: ICD-9 ’630-676’ or 
ICD-10 ’O00-O99’ aged 15 – 54 years, 1987 – 2010, 
n = 1 378 544
PPCM or idiopathic pregnancy-associated HF
n = 272
Women admitted with a diagnosis of 390-459, 745-747, 759W, 759W, 758A, 
758G (ICD9) or I00-I99, Q20-Q28, Q87.1E, Q87.4, Q90 & Q96 (ICD-10) 
within one year of an obstetric diagnosis code
n = 11906
Cases with a HF diagnosis code and/or a PPCM code ICD-9 or ICD-10
n = 350
Cases, n = 11 284 were assigned
Controls, n = 56 379, matched 1:5* for maternal age and year of delivery
Cases excluded due to proxy diagnosis 
outside time band or No HF diagnosis
(-30 days to + 180 days)
n = 10 934
Figure 3. Flow-chart, inclusion of PPCM cases.
PPCM in western Sweden – III & IV
The study population comprised PPCM cases from fi ve hospitals in western Sweden 
(Sahlgrenska University Hospital, Södra Älvborgs Sjukhus, Halmstad Sjukhus, Norra 
Älvsborg Länssjukhus, and Kärnsjukhuset Skövde) with a catchment area constituting 
20% of all Swedish deliveries. All departments of cardiology/internal medicine in the 
region were contacted to identify women with a PPCM or any idiopathic pregnancy-
associated HF diagnosis from 2004 – 2013.  Patient records were followed from pre-
sentation to the date of the fi nal review (October 13th 2013).
Consecutive patients were identifi ed in a two-prong process:
1)  For hospitals outside Gothenburg where the authors had no access to the medical 
records, the chief physicians from all departments of cardiology/medicine were 
contacted who then identifi ed cardiologists within their respective departments 
known to have a special interest in pregnancy-associated HF, who could then aid 
in the transfer of medical records of PPCM cases to the authors. Because PPCM is 
rare in Sweden, these cases were easily identifi ed. Through this procedure, a total 
of 6 cases were identifi ed, 4 of which fulfi lled the inclusion criteria. 
*Only 16 cases had less than 5 matched controls
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2)  Within Gothenburg - which comprises one tertiary referral hospital, the Sahlgren-
ska University Hospital - the authors had direct access to the electronic records. 
ICD-codes and journals were reviewed for any women aged 15 – 54 years who 
were discharged from the hospital between January 2004 and October 2013 with an 
ICD-10 diagnosis code of PPCM, HF or cardiomyopathy (O90.3, I50, I42 and I43). 
Women lacking a concurrent obstetric ICD-codes were excluded as non-pregnant. 
By these criteria another 31 cases were identifi ed. Six of these were excluded be-
cause they were lost to follow-up, most having moved out of the region. Another 
5 did not meet the PPCM criteria, leaving 20 cases in Gothenburg for inclusion. 
For the echocardiographic and arterial assessment review, 17 healthy controls were 
identifi ed, recruited through local advertisement. Inclusion criteria for the controls 
were: 
1)  At least one past pregnancy and delivery with emphasis on the absence of any com-
plication including mild gestational hypertension or diabetes. 
2)  Freedom of any past or present cardiovascular disease.
3)  Freedom of any current health issue requiring medical supervision, medication or 
which would interfere with the data collection.
Upon investigation, two controls were excluded – one because of LV wall motion 
abnormalities, and a second case due to bicuspid aortic valve disease, both fi ndings 
potentially affecting LV loading conditions and arterial compliance.
The registries
Sweden has universal healthcare providing low-cost hospital care to all Swedish per-
manent residents. As the vast majority of Swedish residents are managed within the 
public healthcare system, data keeping becomes equally manageable. Therefore when 
hospitals are obliged to report data to national registers, coverage tends to be high. It 
is this high coverage, accuracy and the long time span within which these registers 
have been available, that has allowed for the high data quality used in this thesis, and 
which has ultimately allowed for an unusual complete dataset.55-57 The registers used 
cover deaths, hospitalisations and births.
The Cause-Specifi c Death Register
The CDR includes death certifi cates and autopsy reports for all Swedish residents 
dating back to 1961. The international version of the ICD-10 is currently employed. 
The CDR was validated in one report from 1995 which showed an accuracy of 87% 
for ischemic heart disease, but generally stated that the more sudden the death and the 
younger the person, the higher the validity. The latest report from the National Board 
of Health and Welfare states that 3% of diagnoses are given a faulty code, but only 
0.3% of ICD-10 codes remain incorrect by the time they are entered into the CDR. It 
also states that whereas autopsy was performed in 50% of decedents in the 1970s, that 
number has shrunk to 20% today.58
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The Inpatient Register
The Inpatient Register (IPR) collects all diagnosis codes on discharge for any patient 
in the entire country. Since 1987 reporting discharge diagnoses for all hospitalisations 
to the nationwide IPR has been mandatory. The data are person-based and include 
primary and secondary discharge diagnoses of any given hospitalised patient 56. From 
1987 to 1996, a primary discharge diagnosis was lacking in less than 1% of all ad-
missions. The diagnosis of HF in the Swedish Inpatient register has been validated 
showing 96% accuracy for primary diagnoses in internal medicine or cardiac wards, 
and 86% and 91% for secondary diagnoses in internal medicine and cardiac wards, 
respectively.59 From 1987–1996, a primary discharge diagnosis in the IPR was lacking 
in less than 1% of all internal medicine and cardiac ward admissions. The diagnosis 
of HF in the IPR has been validated for the period 1976-2001, showing 95% ac-
curacy for primary diagnoses and 91% accuracy for secondary diagnoses in cardiac 
wards.56, 59 Unpublished data from a study in metropolitan Gothenburg showed that a 
cardiomyopathy diagnosis could be validated in nearly 90% of the cases. No change 
in diagnostic accuracy was seen over time.
The Medical Birth Register
Since 1973, 97.0–99.4% of deliveries have been reported to the Medical Birth Reg-
ister (MBR) which includes information from the fi rst antenatal visit up to the last 
perinatal care.57, 60 The most extensive validation of the MBR from 2002 and the latest 
report from the MBR, Pregnancies, Deliveries and New born Infants from 2012, both 
written in liaison with the National Board of Health (Socialstyrelsen), found missing 
MBR registrations in 1.0% (1973–1998) and 0.6% (2010) of cases respectively. The 
MBR prior to 1998 did not distinguish between singleton and multiple births, but 
ICD codes from IPR allowed us to assess this information. An increasing number of 
deliveries among mothers born outside the Nordic countries was seen: 3% in 1973 
and 21.5% in 2010. Further an unknown number of these deliveries took place prior 
to registering with the Swedish authorities and likely went unreported.56, 60 
Defi nitions and procedures
Paper I
First admission was defi ned as any hospital admission with no previous admission for 
HF in the past seven years. This was done to ensure the probability of being admit-
ted for the fi rst time was similar for any given time period. We defi ned the employed 
diagnosis codes as follows: 
ICD code ICD-9 (1987 – 1996) ICD-10 (1997 – 2006) 
Cardiomyopathy 425 I42, I43 
HF 428A, 428B and 428X I50 
IHD 410-414 I20–I25 
Valvulopathy 391, 394-398, 421, 424 I05-I09, I33-I39 
ACHD 745-747 Q20–Q28, Q87, Q89 




Data for the controls were extracted from the MBR and IPR. Mean parity was de-
fi ned as the number of deliveries including the index delivery. Assisted pregnancies 
were defi ned from data from the MBR as: in-vitro fertilisation (IVF), intracytoplasmic 
sperm injection (ICSI) or high-dose hormonal therapy. Caesarean section included 
both acute and elective procedures as defi ned in the MBR. Preeclampsia was defi ned 
by IPR data, and codes 642 (ICD-9) and O11–O15 (ICD-10). Comorbidity diagnosis 
codes were collected from the IPR for both cases and controls. Diabetes was defi ned 
by codes 250 (ICD-9) and E08–E13 (ICD-10) and I10 – I15 (ICD-10), and thyroid 
disease as codes 240–246 (ICD-9) and E03–E07 (ICD-10). Nationality was defi ned 
as the mother’s country of birth and an Organisation for Economic Co-operation and 
Development (OECD) country as member states at the beginning of the study period. 
Neonate characteristics adhered to the standard defi nition of small for gestational age 
(SGA), referring to a birth weight <2 standard deviations smaller than the average and 
large for gestational age as >2 standard deviations larger than the average.61
Paper III
Maternal age was determined at the time of delivery. Body mass index (BMI kg/
m2) was measured at fi rst antenatal visit (9–12 weeks of gestation). Normotensive 
was any BP <140/90 mmHg. Parity was the number of deliveries per woman includ-
ing the index pregnancy delivery. Assisted pregnancy included the following fertility 
enhancing methods: in-vitro fertilization (IVF), intra-cytoplasmic seminal injection 
(ICSI) and assisted hormonal therapy. All non-elective caesarean sections (CS) were 
classifi ed as acute. Gestational diabetes was classifi ed as the development of diabetes 
in any pregnant woman with no known pre-existing diabetes. Preeclampsia was de-
fi ned as proteinuria and new onset hypertension after 20 weeks of gestation. Clinically 
signifi cant postpartum hemorrhage was defi ned as estimated blood loss of >500 ml 
within 24 hours of delivery.62 Small for gestational age (SGA) was defi ned as a birth 
weight of less than the 10th percentile for gestational age assuming 3500 g as the mean 
birth weight at 40 weeks of gestation in Sweden during the period.60 Preterm birth was 
delivery before 37 weeks of gestation. Substance abuse was defi ned as any mention 
of clinically relevant illegal drug use in the medical records. Self-reported alcohol 
consumption was recorded at the fi rst antenatal visit, and at 30 weeks gestation. Left 
ventricular mass was indexed to patient height.63
Paper IV
The commercially available sonography machine (Philips E33 Andover, MA, USA) 
was used and images stored digitally. Images were recorded by an experienced echo-
technician or cardiologist at the department of physiology at Sahlgrenska university 
hospital. Images were acquired at rest and during stress in accordance with current 
guidelines.64 Reporting was performed by two independent readers, blinded to clini-
cal data and patient identifi cation. Standard 2-D measurements of LV size and mass, 
LVEF (Teicholz) and Simpson’s method (mode of discs) were performed in adherence 
to current guidelines.64 Contractile cardiac reserve was defi ned as LVEF and -car-
diac output and was calculated from images acquired at rest and during submaximal 
stress. Early (E), and atrial (A) trans-mitral infl ow velocities were measured. In apical 
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4-chamber view we registered, tissue Doppler atrioventricular (AV) plane long-axis 
velocity, at the lateral and septal border of the LV, and at the RV free wall. Systolic 
velocity, (s’) and early diastolic velocity, (e’) were measured. E/e’-ratio, an index of 
LV end-diastolic fi lling pressure was calculated using the mean value of lateral and 
septal recordings. Further tissue Doppler derived isovolumic contraction (ICT) and 
relaxation times (IRT), ejection time (ET) were measured at the level of the septal AV-
plane. LV myocardial performance index, (MPI) is an index of both systolic and dia-
stolic dysfunction and is calculated as MPI = (ICT+IRT)/ET).65 Global longitudinal 
strain (GLS) based on echo speckle tracking was measured in apical views (Table 2).
Cardinal echo parameters Explanation 
LVEDD Left ventricular end-diastolic diameter  
LVESD Left ventricular end-systolic diameter 
LVEF Left ventricular ejection fraction 
LA Left atrium 
E/A-ratio Trans-mitral inflow maximal velocity during 
early (E) and atrial (A) diastolic phases 
s’ Tissue Doppler derived atrioventricular (AV) 
plane long-axis velocity – in systole 
e’ Tissue Doppler derived atrioventricular (AV) 
plane long-axis velocity – in diastole 
E/e’-ratio LV filling pressure (indirect pulmonary 
capillary wedge pressure)
Cardiac contractile reserve ?Cardiac output at rest and during stress 
Myocardial performance index Myocardial effectivity (ejection time vs. 
isovolumetric systo-diastolic times)2
Global longitudinal strain Summation of left ventricular longitudinal 
deformation using Q-lab’s cardiac motion. 
Table 2. Cardinal echocardiographic parameters
For arterial stiffness assessment, PWV measurements were recorded with the patient 
in the supine position. No sleeping or talking was allowed during measurements. Ar-
teriograph©, a non-invasive device which only requires an upper arm cuff and the 
distance from the jugular notch to the pubic protuberance (an approximation of the 
length of the descending aorta) was used. Based on sphygmomanometric measure-
ments, it uses an algorithm to calculate PWV, AIx and dP/dt relying on the premise 
that the oscillatory pulse waves are refl ected, crucially at the iliac artery junction, or 
as the aorta branches out. The time elapsed between the direct pressure wave (P1), 
and the refl ected pressure wave (P2) reach the brachial cuff, allows for determination 
of PWV (m/s), AIx, aortic (%), AIx, brachial (%) and (dP/dt) (mmHg/s). AIx, bra-
chial was calculated directly from the pulse pressure wave at the cuff level, whereas 
AIx, aortic was estimated from an empirically derived regression algorithm which 
estimates indirect central aortic pressures changes. Both AIx, aortic and AIx, bra-
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chial were normalized to 80 beats per minute (bpm). Arteriograph© has been validated 
against SphygmoCor© and invasive recordings. Both Arteriograph© and Sphygmo-
Cor© were independently strongly correlated with invasive recordings (Table 3).53, 54 
Parameters of arterial stiffness Explanation 
Arterial compliance Volume change due to incremental pressure 
change (C = ?V/?P) (ml/mm Hg).
PWV, Pulse wave velocity Speed with which the oscillatory pulse propagates 
from the LV out the aorta and adjacent vessels 
(m/s). 
AIX, Augmentation index ?P – between direct and reflected systolic peak 
pressures, divided by the pulse pressure, (PP); 
(Preflected-Pdirect)/PP x 100) (a ratio). 
dP/dt max LV maximal pressure rise measured at the brachial 
cuff level in early systole. 
Table 3. Parameters of arterial stiffness
Statistical methods
While paper I and II are epidemiological studies that warrant parametric tests, paper 
III and IV are clinical low population studies, where non-parametric tests are appro-
priate. In paper II and IV case-control study designs were chosen. 
Paper I
Annual HF incidence rates per 100,000 person-years and 95% confi dence intervals 
(CIs) were calculated using the method of direct standardisation, using the median 
year 1996 as a standard. Descriptive statistics were applied to summarise the comor-
bidity prevalence within the identifi ed HF population. In addition, we used joinpoint 
regression for estimation of the annual percentage change and to fi nd the specifi c years 
when signifi cant changes in the trends occurred (Joinpoint Regression Program, ver-
sion 3.3.1. April 2008; Statistical Research and Applications Branch, National Cancer 
Institute). We fi tted the data in a log-linear model and set the number of possible join-
points between 0 and 3. For each estimate of mean annual percentage change, 95% 
confi dence intervals were calculated. Further, one-year, age- and sex-specifi c case 
fatality rates were calculated up to one year after admission in patients aged 18 to 34, 
35 to 44, 45 to 54 and 55 to 84 years over the periods 1987-1991, 1992-1996, 1997-
2001 and 2002-2006. To estimate changes in one-year case fatality, hazard ratios for 
each time period of hospitalisation were calculated by means of Cox regression with 
the period of 1987-1991 as reference, and adjusted for age, sex, diabetes, ischemic 
heart disease, cardiomyopathy and adult congenital heart disease and/or valve disease. 
Kaplan–Meier survival curves were applied to illustrate three-year case fatality. 
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Paper II
All data were analysed using SAS 9.3. To assess differences in baseline characteris-
tics between cases and controls, the χ2 test was used for dichotomous variables, and 
the t-test for continuous variables. Odds ratios were obtained using bivariate logistic 
regression. Multivariate logistic regression was used to estimate independent factors 
of importance with respect to differences between cases and a) matched controls, and 
b) all controls. Signifi cance was assumed at P<0.05.
Paper III
Statistical analysis was performed using MedCalc for Windows, version 12.7.5 (Med-
Calc Software, Ostend, Belgium) and IBM© SPSS© version 21. Non-parametric tests, 
Mann-Whitney U analysis for independent data and Wilcoxon’s test for paired data 
were used. Fisher’s exact test was used to assess mean differences for categorical data 
or when data did not meet the criteria of other non-parametric tests. Data are presented 
as mean (SD). A two-sided P<0.05 was considered signifi cant.
Paper IV
Data are described as mean (SD). Time to investigation was defi ned from the time 
of delivery to the date of cardiovascular examination. All continuous data between 
cases and controls during follow-up were compared using Mann-Whitney U tests with 
no assumption of distribution (exact test). For comparison of categorical variables 
between groups, Fisher’s exact test was used. Two-sided P<0.05 was considered sig-
nifi cant. All analyses were performed with IBM© SPSS© Statistics version 21 (IBM 
Corp, Somers, NY). 
Ethical considerations
All four papers were approved by the local ethical committee of Gothenburg Univer-




Table 4 illustrates the divergent trends in HF hospitalisation between younger and 
older patients. Whereas hospitalisation in the 55-84 year age group peaked in 1992 to 
1996 at 854 per 100,000 decreasing to 603 per 100,000 in 2002 to 2006, HF hospitali-
sation among persons <45 years increased throughout the entire observation period. 
Trends among persons aged 45-54 years were similar to those aged 55 to 84 years 
with a less marked decrease after 1996. A joinpoint analysis confi rmed the continuous 
increase throughout the period for the 18-34 year age group, and from 1999-2006 for 
the age group 35-44 years. Further in adults >45 years a rising then falling pattern was 
seen 1994 signifying the marked breaking point for a decline in heart failure rates.
Age group  1987-1991 1992-1996 1997-2001 2002-2006 
18 -34 n 266 312 319 387 
Per 100 000  2.5 2.8 2.9 3.7 
HR (95% CI)  1.00 1.15 1.19 1.5 
35-44 n 706 875 814 981 
Per 100 000  10.2 13.6 12.7 14.6 
HR (95% CI)  1.00 1.33 1.25 1.43 
45 -54 n 2 456 3 830 3 806 3 415 
Per 100 000  46.2 59.6 55.6 53.6 
HR (95% CI)  1.00 1.29 1.20 1.16 
55 -84 n 105 741 125 138 102 067 92 882 
Per 100 000  719 854 688 603 
HR (95% CI)  1.00 1.19 0.96 0.84 
Table 4. Incidence of fi rst hospital admissions for heart failure per 100 000 person 
years in Sweden 1987 to 2006 by age, sex, and period. HR, hazard ratio
From 1987 - 1991 to 2002- 006, the mean incidence of HF with cardiomyopathy more 
than doubled in all age groups (HRs 2.0 to 3.0). In patients <55 years this was not at 
the expense of other diagnoses as the incidence of HF from other causes not related to 
IHD or cardiomyopathy also increased. 
In pregnancy-associated HF an increasing trend was also seen. The cumulative inci-
dence of PPCM for the period was 1 in 9 191 deliveries, increasing from 1 in 26 226 
deliveries from 1987-1991 to 1 in 4521 deliveries for 2007-2010. The proportion of 
PPCM cases of non-OECD origin increased from 18% in 1987–1991 to 31% in 2007-
2010 which suggests a positive trend, P=0.03 (Figure 4).
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Mortality 
In paper I, one-year case fatality at the beginning of the study period was high in all 
age groups, with about one in four dead at ages 18-54 years and 39% >55 years.  From 
1987-1991 to 2002-2006 a marked adjusted one-year relative case fatality reduction 
of 60-62% at 18-44 years was observed, and correspondingly 56% and 38% at 45-54 
and 55-84 years respectively. Figure 5 demonstrates the survival benefi t was sustained 
up to three years, but that no further signifi cant improvement in case fatality occurred 
in the <55 year age group after 2001.
Figure 4. PPCM incidence/100 000 deliveries in Sweden, 1987–2010. Total incidence, and 


























Figure 5. Kaplan-Meier survival curves. One-year case fatality after fi rst HF hospitalisation in 

























Figure 6. All-cause mortality among cases vs. controls.
In paper II we exclusively looked at mortality among women with pregnancy-asso-
ciated HF. The mean follow-up was 16.4 years with 22 (8.1%) cases, and 5 (0.4%) 
controls dying during the follow-up period, OR 23.5 (95% CI 8.8–62.6). In cases, 
73% of deaths occurred within the fi rst 3 years of diagnosis. In comparison, none of 
the controls died within 3 years of delivery (Figure 6). Mortality among unmatched 
controls was similar to matched controls, with 347 decedents (0.6%) by the end of the 
study period. 
The characteristics of PPCM fatalities versus PPCM survivors did not differ signifi -
cantly as the limited number of deaths in the PPCM group (n=22) did not provide 
suffi cient statistical power to assess independent factors related to a fatal outcome. 
Autopsy was performed in 7 cases (31.8%). HF was stated as an underlying cause of 
death in 11 (50%) patients, 7 of whom had concomitant cardiomyopathy. Other car-
diovascular disease related deaths included stroke with cerebral herniation, acute pul-
monary embolism, and two cases of diabetes. The primary non-cardiovascular causes 
were: lung cancer, breast cancer, non-Hodgkin’s lymphoma, substance abuse (n=3), 
and one death of unknown cause. Among the 11 HF case fatalities, the mean/median 
time to death was 1.9/0.6 years compared with 5.7/3.0 years among the 11 non-HF 
related deaths (NS). Only 5 matched controls died, but mean time to death among 
fatalities in the unmatched control group (n=33) was 11.7 years.
Among PPCM survivors and fatalities statistical differences could not be assessed 
because of the low number of observations, but age and BMIwere numerically similar.
Diabetes was 6 times more common in fatal cases, however, confi dence intervals were 
wide (OR 6.4, 95% CI 1.5-27.7). Mean number of in-hospital days for fatalities was 
16.0 compared with 7.4 for survivors. 
Mortality in paper III was confi ned to one case at 10 months postpartum. The 4.8-year 
mortality in the study remained at one death in 24 cases (4.1%).
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Figure 7. Comorbid prevalence (%) of mutually exclusive diagnoses among HF 
patients of different ages.
Comorbidities and clinical characteristics 
In the fi rst paper it was seen that the overall burden of comorbidity in a young Swed-
ish HF population was substantial. Of patients aged <45 years, 21% had IHD with 
15% having acute myocardial infarction (MI). Fourteen per cent had diabetes, 4% a 
prior stroke and 8% any cancer. For patients aged 45 to 54 years, IHD, MI and dia-
betes, stroke and cancer was found in 39%, 27% and 20%, 5% and 9% respectively. 
Concomitant cardiomyopathy was registered in 20% of those aged <45 years and in 
13% of those aged 45-54 years. Cardiomyopathy increased from 15% to 25% and 
from 9% to 15% over the four periods in the <45 and 45 to 54 age groups respec-
tively. Concomitant valve disease and ACHD among patients younger than 45 years 
remained stable throughout the study. About 5% had no other diagnosis than HF (data 
not shown).
Figure 7 shows the mutually exclusive categories of comorbidities by age over the 
entire study period. The proportion of IHD-related HF hospitalisation increased sub-
stantially with age, whereas cardiomyopathies decreased. The proportion of patients 
diagnosed with ACHD was 12.0% among the youngest age group and 0.3% among 
the oldest. The proportion with valve disease and ACHD did not change materially 
over time in any age group. The prevalence of the combined common aetiologies of 
IHD, diabetes and hypertension below the age of 55 years was stable throughout the 
study period in patients <55, but not in older patients (increase 54% to 66%), chiefl y 
as a result of a decrease in other causes. Cardiomyopathy increased across all age 
groups. A closer look at the large and heterogeneous group of patients labelled ‘other’ 
revealed no qualitative differences between the fi rst and the last periods, the most 













In paper II, exclusively looking at comorbidities in women with PPCM, a multivari-
able analysis approach taking relevant potential causal factors into consideration, was 
employed. Patients with PPCM, compared with matched controls, had higher BMI 
(multiple-adjusted odds ratio (OR) 1.05 per unit, 95% confi dence interval (CI) 1.02-
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Cases vs matched  controls 
(204 cases, 1121 controls) 
Cases vs all controls 
(204 cases, 43,654 controls) 
Adjusted 
OR 95% CI P-value 
Adjusted  
OR 95% CI P-value 
Variable
Age, per 10  years 0.94 (0.71–1.24) 0.68 1.50 (1.17–1.91) 0.001 
BMI, per unit 1.05 (1.02–1.08) 0.001 1.07 (1.04–1.10) <0.001 
Born outside OECD country  1.61 (1.07–2.43) 0.02 2.00 (1.43–2.80) <0.001 
Multiple birth, yes/no  2.26 (1.20–4.23) 0.01 2.69 (1.70–4.26) <0.001 
Diabetes* 1.93 (0.34–10.89) 0.45 2.21 (0.78–6.28) 0.14 
Assisted pregnancy, yes/no 1.58 (0.81–3.11) 0.18 1.65 (0.98–2.80) 0.06 
OR, odds ratio; CI, confidence interval; *Pre-existing and gestational disease included.
Table 5. Multivariable analyses comparing PPCM cases and controls matched for age and year 
of delivery to PPCM cases and all controls
1.08), were more likely to be born in a non-OECD country (OR 1.61, 95% CI 1.07-
2.43), have twins or triplets (OR 2.26, 95% CI 1.20-4.23). Diabetes and assisted preg-
nancy were not independently associated with PPCM. Comparison with all controls 
demonstrated an independent association between age and PPCM (OR: 1.50 per 10 
years, 95% CI 1.17-1.91). The estimate for BMI, multiple births, and country of birth 
increased slightly (Table 5).
The time of diagnosis clustered around the time of delivery with 29.4% of cases diag-
nosed in the last month of pregnancy and 82.3% within a month prior to or immedi-





















Figure 8. Time of diagnosis in relation to delivery. Months before/after delivery, n=272.
In paper III more detailed data was obtainable due to having access to the complete 
medical records including laboratory results and serial echocardiography. 
The mean patient age among PPCM patients was 34.2 (5.0) years. Eighteen women 
(75%) were >30 years old at delivery. Postpartum presentation of PPCM occurred in 
20 (83%) patients; of these 20 patients, it occurred within the fi rst week in 11 (55%). 
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The average BMI at the fi rst antenatal visit was 24.6 (3.8); six patients (25%) were 
obese. Seven patients (36.4%) consumed alcoholic beverages regularly at the time of 
conception. Comorbidities at conception included four patients with past or present 
depression, two with asthma, two with recurring migraine, and two with adult con-
genital heart disease not associated with HF (one patient with a restrictive ventricular 
septal defect with prior embolic stroke to the retinal artery and one with a known 
atrial septal defect with transient ischaemic attack). Eight patients (36.4%) had fertil-
ity problems, three of whom became pregnant after in vitro fertilization and one of 
whom became pregnant after hormone treatment. The mean/median gestational age 
at delivery was 35.2 (5.1)/37 weeks. Postpartum haemorrhage occurred in 39.1% of 
the patients. Ten patients were transferred to the intensive care unit (ICU) at the time 
of hospital admission. Five of these 10 patients had pulmonary oedema and received 
respiratory support. The NT-proBNP level was available in 17 patients (mean, 6636 
























Figure 9. Serial natriuretic peptide levels at diagnosis and postpartum in all patients.
Five twin deliveries were recorded. Fifteen neonates were premature, including four 
of the twin sets. Sixteen mothers had underwent acute CS necessitated by preeclamp- 
sia or HF. The CS rates among preeclamptic and non-preeclamptic patients were 85% 
and 56%, respectively. Only one delivery was documented as spontaneous and unaid-
ed. Nine neonates (31.0%) were <2500 g, but only 3 (11.1%) were SGA. No stillbirths 
were recorded, and all infants were alive at the time of the review. 
In paper IV a substantial overlap was seen. Here a total of 37 subjects, 22 cases and 
15 controls were included. Mean follow-up after diagnosis was 3.0 (2.2), (range 0.46–
7.0) years in cases. Maternal age did not differ between cases and controls. BMI 
trended to be higher among cases, 26.9 vs 24.0, P=0.11. Although 12 of 22 cases were 
still on HF medication, both systolic and diastolic blood pressure was signifi cantly 
higher among cases, 122/76 mmHg (range 107/50-139/91) vs 111/67 (range 98/54-
140/84) among controls. Serum creatinine in cases was higher than among controls, 
but within normal range, 65 vs 58 mol/L. Of the 22 cases, 81% were in NYHA-I. 
NT-proBNP was elevated in 27.3% of the cases.
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Pharmacological management
In paper III all patients received -blockers for a mean duration of 20.9 months. 
Twelve received metoprolol, eight received bisoprolol, and four received carvedilol. 
Metoprolol was the preferred -blocker in breastfeeding mothers because was is re-
garded as safest. Metoprolol was discontinued in four patients because of side effects, 
the most common being lethargy, bradycardia, dizziness, hypotension, nightmares, 
and mood swings. Two of these patients were subsequently started on bisoprolol, and 
one was started on carvedilol. Angiotensin-converting enzyme inhibitors/angioten-
sin II receptor blockers (ACE-I/ARBs) were initiated in all patients, but only during 
the postpartum period (mean duration, 32 months). Ramipril was used in 12 patients 
(50%), enalapril in 4, and candesartan in 8. Seven patients were switched to candesar-
tan because of side effects of ACE-I; two because of angioedema and fi ve because of 
a dry cough or other respiratory symptoms. Fifteen patients received intravenous loop 
diuretics, and 16 received oral furosemide. Ten patients (43.5%) were commenced 
and maintained on a mineralocorticoid receptor antagonist (MRA) (exclusively spi-
ronolactone), while the 14 remaining experienced hypotension and dizziness why 
MRA was not initiated. Six patients received an oral anticoagulant: four because of an 
LVEF of <25%, and two because of postpartum thromboembolism (Table 6).







ACE-Is/ARBs 24/24 (100.0) 0.1 (0.1–10.1) 138.8 
?-blockers 24/24 (100.0) 0.1 (0.0–14.7) 91.1 
MRAs 10/23 (43.5) 0.9 (0.4–19.9) 40.2§*
Oral loop diuretics 16/24 (66.7) 5.1 (-2.7–14.3) 22.3 
Coumarins (warfarin) 6/24 (33.3) 8.0 (2.0–21.6) 36.8 
Table 6. Pharmacological management of peripartum cardiomyopathy
Seven patients stopped breastfeeding before 2 weeks postpartum; six of these received 
the dopamine agonist bromocriptine administered according to the protocol described 
by Sliwa et al.66 Only four patients continued breastfeeding beyond 2 months. Wors-
ening HF was seen in one patient when her HF medication was discontinued by her 
primary care physician, but she recovered upon reinstatement of the medication. 
Treatment titration and tapering was primarily governed by the patients’ symptoms, 
LVEF, and natriuretic peptide levels. Treatment was never discontinued earlier than 1 
year after normalization of the LVEF and achievement of NYHA class I. At the time 
of the review, seven patients were still on medication, and two of these had residual 
dyspnoea. Among the remaining 16 surviving patients, -blockers and ACE-Is were 
discontinued without any cases of worsening HF after a mean duration of 1.8 and 2.7 
years, respectively. 
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PPCM & Preeclampsia - paper II, III & IV
Preeclampsia was associated with PPCM evidenced in papers II, III and IV. In paper 
II the OR for preeclampsia was 13.02, (95% CI 8.41-20.15), which decreased to OR 
9.56, (95% CI 7.08-12.91) if compared to all controls as opposed to matched controls 
only. One percent of cases with concomitant preeclampsia died, compared with 12.2% 
of cases with PPCM only, OR 13.8 (P=0.001).
In paper III 14 (58.3%) developed preeclampsia at a mean of 30.8 (5.3) weeks of 
gestation. All 24 patients were normotensive at the fi rst antenatal visit. Patients with 
preeclampsia had lower parity and more frequent headaches, eye symptoms and nau-
sea; in contrast, dyspnoea was the cardinal symptom among women with PPCM only. 
Patients with preeclampsia (this group included all patients who developed pulmo-
nary oedema) also had higher ICU admission rates. Preeclamptic women also had 
higher LVEFs both at presentation (P=0.02) and at the time of the review (P<0.001). 
All patients with preeclampsia had an LVEF of ≥50% at 12 months and 11 of the 14 
patients with preeclampsia were in the early recovery group. In contrast, only 4 of the 
10 patients without preeclampsia were in the early recovery group (P=0.04).
In paper IV preeclampsia was prevalent with 14 patients (63.6%) out of 22 patients with 
PPCM. Patients with concomitant preeclampsia did not differ from non-preeclamptic 
cases in regards to mean-follow up, age or BMI; but on average the natriuretic peptide 
level at the time of review was below the clinical threshold for HF compared with 
non-preeclamptic cases at 67 vs 277 ng/L respectively, P=0.02.1 Systolic and diastolic 
LV dimensions were signifi cantly smaller in cases with concomitant preeclampsia, 
P=0.02. LVEF was higher in cases with concomitant preeclampsia (58.9%) vs cases 
with PPCM only (51.7%), but only borderline signifi cant, P=0.07. 
Left ventricular function 
In paper III we assessed LV function in relation to symptomatic recovery. Early symp-
tomatic recovery (NYHA I in ≤1 year) was seen in 13 patients. Of the remaining 11 
patients, 7 had reached NYHA I by the time of the review. The mean time to NYHA I 
among the patients in the arbitrarily defi ned early recovery group and among the sur-
vivors in the late/non-recovery group was 4.8 and 30.2 months, respectively (Figure 
10). One case of sudden death occurred 10 months postpartum in a stable patient that 
had clinically improved but had persistent LV dysfunction (LVEF of 40%). 
The mean time to normalization of NT-proBNP (<125 ng/L) was 8.2 and 16.4 months 
in the early and late/non-recovery groups, respectively. Only one patient had an el-
evated natriuretic peptide level at 3 years postpartum. The presence of preeclampsia 
tended to be positively associated with early recovery (P=0.08). 
LV recovery was assessed by serial TTE (see also Figure 11). The time to last TTE 
was not signifi cantly different between the two groups (P=0.39). The mean LVEF 
from presentation to review was 21.2% and 21.3% in the early and late/non-recovery 
groups, respectively. In the early recovery group, 10 (92%) patients had an LVEF of 





















Figure 10. Symptomatic recovery. Proportion of patients with NYHA I at ≤1 year (early recovery) 
vs >1 year (late/non-recovery).
non-recovery group. The LV end-diastolic diameter at presentation was positively as-
sociated with late/non-recovery (P=0.02). Conversely, patients in the late/non-recov-
ery group had higher end-systolic diameters at the time of the review (P=0.02). The 
LV mass index decreased in all patients individually, but the difference between the 
early and late/non-recovery groups was not statistically signifi cant. 
In paper IV measurements of resting echocardiography revealed important differ-
ences between cases and controls as described. At rest cases had structurally larger 
hearts with higher systolic and diastolic LV volumes and LV mass index (LVMI). 
LVEF<50% was more prevalent among cases (6 out of 22 cases vs 0 out of 15 con-
trols, P=0.05). E wave peak velocity was lower in cases, and so were both septal 
systolic and early diastolic longitudinal tissue Doppler AV plane velocities, s’ septal 
(7.5 vs 8.6 cm/s, P=0.01) and e’ septal (9.2 vs 11.5, P=0.004). MPI differed in controls 
vs cases, (controls, 0.37 vs 0.53, P<0.001). Resting echo vs stress echocardiography, 
did not reveal signifi cant difference between cases and controls neither during stress, 
nor in terms of -cardiac output which increasing from 4.1 to 7.5L in cases, and 3.7 to 
7.6 L/min in controls respectively, P=0.51 mean HR during stress 125 (99–144) bpm.
Arterial stiffness
In paper IV arterial stiffness was compared between PPCM patients and controls. HR 
at rest was similar in controls and cases, but the increase was more pronounced in 
cases vs controls (19 vs 12 bpm respectively). Arterial compliance was reduced in 
cases as both PWV, aortic and brachial AIx trended to be higher at rest and were sig-
nifi cantly higher post-stress: PWV 8.9 vs 7.6 m/s, P=0.006; AIx, aortic 15.8 vs 4.9%, 
P<0.001 and AIx brachial, -24.8 vs -65.0, P<0.001. However, we did not see any 




Among young patients with HF, we observed an increase in hospitalisation which 
was divergent from the continuing decrease after 1992 -1996 seen among patients 
older than 54 years of age. The incidence of concomitant cardiomyopathy more than 
doubled during this period in all age groups. Mortality in young patients was reduced 
by more than half, but with no further decrease after 2001. 
Among women with PPCM we used the unique approach of combining several na-
tional registries, to identify a cohort of 272 patients with PPCM or pregnancy-asso-
ciated HF over a period of 24 years, further emphasising the rarity of this condition 
in a Western population. Compared with age-matched controls, cases more often had 
preeclampsia, twins or triplets, were obese, or were born outside an OECD country. 
Just over 8% of cases died during follow-up, with two thirds of fatalities occurring 
within 3 years. Preeclampsia was strongly linked to PPCM but inversely associated 
with mortality.
In a clinical cohort of 24 women with PPCM, 5-year prognosis was favourable even 
though half required ICU admission and only one-third were asymptomatic 3 months 
after delivery. LV dilatation at presentation was the best predictor of recovery later 
than one year. Women with concomitant preeclampsia had a more acute presentation, 
but experienced faster LV and symptomatic recovery. 
Systolic and diastolic function, and arterial stiffness in 22 PPCM patients three years 
after diagnosis, revealed clinically signifi cant pathological markers when compared 
with 15 healthy controls. Patients, whether recovered or not, had higher blood pres-
sures than healthy controls and markers of arterial stiffness were elevated in patients 
evidenced by increased PWV and AIx.
HF and PPCM incidence
HF incidence, according to data from Sweden, Netherlands and Scotland has levelled 
off and eventually declined.7, 9, 67, 68 This is also the case in the USA.69 Because HF is 
predominantly a disorder of the elderly, there is a lack of data on trends in younger 
people. Decreasing mortality and increasing readmission rates infl uence hospitalisa-
tion rates, but in our data 97.8% of admissions were unique individuals. For the same 
reason mortality reduction cannot explain the increasing hospitalisation rates. Be-
cause the national discharge registry only reached full coverage from 1987, it was not 
possible to exclude all readmissions within the seven years prior to 1987. However, 
the expected effect on our dataset would be an overestimation, not an underestimation 
of the incidence in the fi rst seven years. Epidemiologic studies of HF in patients <45 
years of age are scarce. The Framingham cohort comprised patients aged 28 to 62 
years, but none of the analyses from that cohort identifi ed enough cases to appropri-
ately address trends in HF in this age group. In a sub-study of the CARDIA cohort, a 
20-year follow-up prospective analysis of 5 115 patients 18 - 30 years revealed new 
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onset HF in a mere 27 subjects.15 Hypertension, diabetes and IHD are major targets 
for reduction of HF. In the CARDIA study hypertension was a major aetiological risk 
factor in the development of early HF. 15 In our HF population diabetes and IHD were 
common and increased with age, but not over time. The rising prevalence of hyperten-
sion in HF patients may infl uence the incidence of HF, but as the validity of this di-
agnosis is poor 56, this conjecture remains speculative. The introduction of reimburse-
ment by diagnosis related groups systems in 1992 may explain some of the increase in 
HF seen in our data between the fi rst two periods, but does not explain the continued 
and accelerating increase in hospitalisation for patients <45 years seen after 1996. 
The incidence of PPCM in paper II was lower than studies from South Africa19 and 
lower than most US register data,20, 22, 28 but higher than data from Japan.24 The inci-
dence increased continuously throughout the study period, but changing from ICD-9 
to ICD-10 may have infl uenced data. Heightened awareness, improved diagnostic 
testing and case recognition over the years may have increased the number of ob-
served cases, but it is unlikely that pregnant women with overt HF would be more 
likely to be managed out-patient in the early parts of the study period, especially as 
the admission threshold has continued to increase since 1980.70 Therefore, increasing 
maternal age, rising obesity, and an increasing number of non-OECD born women 
among PPCM cases in Sweden, may have played a role.60 
 
Prognosis in HF and PPCM 
In Swedish patients with HF, one-year case fatality was substantially reduced in all 
age groups from 1987 to 2006. There is a dearth of mortality data among persons <55 
years of age. Rochester population-based data show stable one-year mortality ranging 
from 23% in 1981 to 28% in 1991 (mean age 74 years).71 Another survey from the 
same population (1979 – 2000) reported a 52% survival improvement among men in 
their 60s, but only 28% among men in their 80s, a fi nding congruent with the more 
pronounced case fatality reduction observed among younger subjects in our popula-
tion.72 
Our HF data did not show any further improvement in fatality after 2001. We know 
neurohormonal blockade has improved survival in patients with systolic HF.73-75 The 
largest relative reduction in case fatality occurred from 1987-1991 to 1997-2001, i.e. 
prior to the publication of the landmark trials validating beta-blocking agents in HF 
treatment, suggesting either that beta-blocker treatment had not been fully implement-
ed,74, 75 or did not impact fatality in this population. 
In women with pregnancy-associated HF in Sweden, deaths among cases were >20-
fold that of controls. Almost 3/4 of deaths among cases occurred within 3 years from 
diagnosis, whereas the deaths among the controls occurred evenly across the follow-
up period (Figure 6). Though mortality was somewhat lower than in case series from 
the USA, it was higher than in three large similar register studies from California 
totalling 341 cases.20, 22, 28
Notable geographical differences in PPCM incidence and mortality exist. Like in 
these data, Japanese, German and American PPCM data show lower incidence, lower 
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mortality, and higher prevalence of concomitant preeclampsia24, 26, 28 when compared 
with data from Haiti, Turkey and India where higher incidence, mortality and a less 
pronounced increase in the prevalence of concurrent preeclampsia is seen.45, 76, 77 South 
African studies often exclude women with preeclampsia which precludes direct com-
parison, but both the incidence,19 and especially the mortality is higher than the men-
tioned studies from North America and Germany. Hence, Blauwet and colleagues 
found a 6-month mortality of 13% compared to just over 3% in our Swedish country-
wide cohort presented in paper II.46 Suri and colleagues likewise found high maternal 
mortality, 28%, at 3 months postpartum all dying of congestive HF.78 In contrast our 
data from paper III, comprising the clinical cohort of 24 women studied, only one 
death occurred at ten months after diagnosis equivalent to a 5-year mortality of 4.2%. 
In the same paper prognosis after a PPCM diagnosis was good with more than half of 
the patients achieving NYHA I in less than a year. All patients in the early recovery 
group and 83.3% of those in the late/non-recovery group had recovered by the end of 
the 4.8-year review. In the early recovery group, 50% of the patients achieved NYHA 
I in 100 days as opposed to 700 days in the late/non-recovery group. This overall 
prognosis is markedly better than that reported in South African47 and most American 
studies,32 but is consistent with a recent German cohort.26 
Factors associated with PPCM 
PPCM has consistently been linked to high maternal age.28 In our cohort from all of 
Sweden as presented in paper II, >50% of the patients were ≥30 years. The corre-
sponding fi gure for all delivering mothers in Sweden is 28%.60 Contrary to what was 
reported by Gunderson and colleagues,28 PPCM in our study was not associated with 
increased early infant mortality, but SGA neonates were more prevalent among cases 
than controls (OR 4.9, 95% CI 2.8–8.7). 
As reported in paper II, diabetes and obesity were more prevalent in cases, but in these 
data prevalence was lower. Diabetes, defi ned at discharge, was not independently as-
sociated with PPCM if adjusted for BMI which is congruent with data from a Ger-
man PPCM cohort.26 Although obesity is a known risk factor for the development of 
symptomatic HF in the general population, it has not been proven to be independently 
linked to the development of cardiomyopathy.79 In our population, obesity was more 
prevalent among cases, and because we used weight at fi rst visit (gestational week 
9–12), it is unlikely that water retention would explain the observed difference in BMI 
between cases and controls. 
Mothers born outside OECD member countries were over-represented among cases. 
We could not determine from these data whether this was confounded by socioeco-
nomic status or genetic factors which both are known to be linked to PPCM,47 but the 
parameter remained signifi cant in a multivariable analysis. Data from the Swedish 
Board of Health indicate that among delivering mothers, 47% of African and 27% of 
Asian nationals residing in Sweden had not received any education beyond secondary 
school as opposed to only 8% among Swedish born residents.60 A study from the rela-
tively wealthy Martinique with a mixed population of African heritage showed much 
lower incidence of PPCM than in Haitian or South African cohorts - therefore socio-
economic factors may play a bigger role than previously assumed.80 Swedish registry 
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data further show that after 1990, the number of births from mothers born outside the 
Nordic countries has increased with a notable presence of Somali and Iraqi nation-
als. Our data confi rm an increasing proportion of immigrants of non-OECD country 
origin among mothers with PPCM which also coincides with an increased number of 
immigrants from these countries. Thus the percentage of delivering mothers born of 
African and Asian descent in the study period, increased from 0.5 to 4.2% and 1.7 to 
10.0% respectively.60 
Among the 24 patients that were reviewed in detail, the mean age at delivery in this 
study was high (34.2 years). The mean gestational age at delivery was around 35 
weeks, chiefl y explained by the high CS rates associated with congestive HF and 
preeclampsia. High rates of CS performed due to preeclampsia and acute HF have 
consistently been found in women with PPCM17 and reached 72.7% in the present 
cohort; this rate is 4-fold that of the background population (18%).60 The register data 
from the whole county showed that women with PPCM have higher BMIs,28 but this 
was not confi rmed in this small cohort. Like in the data for the entire country, twin 
pregnancies, were more prevalent in this cohort than in the general Swedish popula-
tion60 of delivering mothers.26, 28 Nine patients (37.5%) experienced postpartum haem-
orrhage; this rate is >7-fold higher than the rate in the Swedish population (5%).82 As 
seen in other cohorts from both Germany and the US,27, 29 neonates of mothers with 
PPCM were more likely to be preterm (43.5% vs 4.0%), be SGA (14.8% vs 4.5%), 
or have low birth weight (<2500 g) (29.6% vs 6.5%) than neonates of mothers in 
the background population.61 Low birth weight is predictably related to preterm de-
livery and associated with increased mortality and morbidity.81, 82 A US study found 
that infants born to PPCM patients had poorer health outcomes and higher mortality 
8.2/1000 and 1.7/1000 births respectively.28 Studies from other parts of the world 
however, reveal much higher infant mortality rates.78
PPCM and concomitant preeclampsia 
Three percent of Swedish pregnancies are associated with preeclampsia,83 but pre-
eclampsia is much more common in the presence of PPCM. In an excerpt of three 
studies of patients with PPCM (n=778), 29%-68% had concomitant preeclamp-
sia.26,32,84 In paper II describing a cohort of the entire country, more than 35% had 
preeclampsia with a multiple-adjusted OR of 13.2. PPCM and preeclampsia share 
many risk factors including low socioeconomic status, high maternal age, multifetal 
pregnancies, and African-American race. They also share pre-existing conditions that 
confer higher risk including chronic hypertension, diabetes, obesity, and connective 
tissue diseases.34 The strong association between preeclampsia and PPCM has led 
to diverging views on whether HF in the presence of preeclampsia constitutes frank 
PPCM or a different disease entity. However, in the majority of pregnant women, 
preeclampsia does not cause reduced LVEF.85 On the contrary, when compared with 
healthy pregnant controls, they exhibit increased fractional shortening, cardiac output, 
and stroke volume indices.86 Likewise, the recent fi ndings in a meta-analysis specifi -
cally addressing preeclampsia and PPCM, support the concept of a shared pathogen-
esis,35 further corroborated by Patten et al who suggest anti-angiogenic properties 
common to both conditions.40 
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In paper III, more than half of the patients in the clinical cohort of 24 patients had 
concomitant preeclampsia. Patients with preeclampsia had higher rates of pulmonary 
oedema and more frequent need for intravenous diuretics, and higher ICU admission 
rates than patients with PPCM only. Although the prevalence of preeclampsia is high-
er among African-Americans and sub-Saharan Africans, studies from South Africa 
have excluded these patients, and while many studies have examined the prevalence 
of preeclampsia in patients with PPCM, Bello et al. contend that the relative prog-
nosis in patients with concomitant preeclampsia is unknown.35 Nevertheless, a few 
studies suggest the occurrence of more rapid recovery in patients with concomitant 
preeclampsia.21, 27 Among this evidence is the data from paper II which shows that 
concomitant preeclampsia was associated with lower mortality. In paper III, we noted 
a shorter time to symptomatic recovery and a higher LVEF, both at presentation and at 
the last 2D-echo examination in patients with concomitant preeclampsia compared to 
patients with PPCM only. The difference in the clinical course, LV performance, and 
prognosis between women with concomitant preeclampsia and women with PPCM 
only, may indicate that they are different disease entities; however, the prevailing 
notion is that these two groups of patients have a shared pathogenesis in which pre-
eclampsia may potentiate PPCM.17
In paper IV concomitant preeclampsia was confi rmed in almost 2/3 of cases. Cockerill 
et al suggested using the Arteriograph© in early pregnancy could serve a practical ap-
plication in gestational hypertensive disorders. They found a tendency towards higher 
PWV at 16 weeks of gestation in women with poor obstetric outcome, compared with 
those with normal outcome, whereas peripheral or central blood pressures did not dif-
fer.87 Our results would support further research into the use of early arterial stiffness 
assessment in pregnancy in order better to detect and care for cases of preeclampsia. 
Also, capillary rarefaction has been shown to precede preeclampsia,88 and structural 
micro- and macro-vascular changes dominate in women a decade after preeclamp-
sia,89 suggesting that PPCM is related to structural changes rather than endothelial 
dysfunction. Our results corroborate the conclusion arrived at by Hausvater et al in 
their meta-analysis of studies investigating the association of arterial stiffness and 
preeclampsia which also saw increased arterial stiffness in women with preeclampsia 
compared with normal pregnancies.37 However, one would expect PPCM cases with 
coexisting preeclampsia would have less compliant arteries than those with PPCM 
only, but our fi ndings suggest similar arterial compliance in these two groups, and in 
the case of PWV measurements, at trend towards the opposite.
LV function and structure in PPCM 
In paper III the cut-off for symptomatic recovery was NYHA I at one year postpar-
tum. Early LV recovery was defi ned as LVEF of ≥50% in ≤1 year. This was seen in 13 
patients, and late recovery in another 6 women in less than two years. One recovered 
later than two years postpartum and three still had persistent LV dysfunction and at 
the end of the study period. There may, however, still be a chance of the last three 
recovering. A Haitian study found that LV recovery continued beyond 5 years.56 Only 
LV dilatation at presentation was signifi cantly associated with subsequent late/non-
recovery, which is congruent with previous fi ndings.23, 46, 90 
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Figure 11 shows the rapid postpartum normalization of LVEF and left atrium size. 
Although even healthy women experience signifi cant haemodynamic changes during 
pregnancy, these changes usually reverse within 2 to 4 weeks of delivery (4–6 weeks 
in women with preeclampsia).16 However, one study showed that the LV mass index 
in healthy pregnant women was still elevated at 8 weeks postpartum.91 The LV mass 
index in a Framingham cohort of healthy non-pregnant women was 47 (7) g/m2.92 All 
patients in the clinical cohort had LV mass indices well above that fi gure more than 
2 years postpartum. As noted, early symptomatic recovery correlated well with LV 
function and NT-proBNP levels at 1 year. The natriuretic peptide level at presentation 
was, however, a poor marker of subsequent outcomes, but correlated well with the se-
verity at presentation (e.g., pulmonary oedema and need of mechanical ventilation). A 
recent study did not fi nd NT-proBNP elevated in healthy pregnant women at 48 hours 
postpartum.93 In contrast, all women in this cohort had elevated natriuretic peptide 
levels, further strengthening the evidence regarding NT-proBNP as a valuable diag-
nostic marker of disease in women with suspected pregnancy-associated HF toward 
































Figure 11. LVEF and left atrial size at diagnosis and postpartum in all patients.
In paper IV review three years after diagnosis revealed similar LVEF in patients vs 
controls, however, comprehensive echocardiographic evaluation revealed important 
alterations in both LV structure and function in patients. LV systolic and diastolic 
diameter and LV mass was still increased. Patients had impaired LV longitudinal func-
tion with reduced septal velocities in both systole and diastole, a pattern often seen 
in hypertensive disease.94 That the septum was more affected than the lateral wall 
might be due to geometrical factors, as the curvature of the septum is less pronounced 
than that of other LV segments and the wall stress of the septum is higher making the 
septum more affected by high LV afterload.95 The decrease in e’ among cases refl ects 
slower ventricular diastolic relaxation, a sign of reduced diastolic function, but as the 
mitral E wave was decreased, the E/e’-ratio remained unchanged indicating similar 
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LV fi lling pressures among cases and controls. RV e’ was reduced indicating affected 
RV function, has been found in hypertension96 GLS has been found to be lower in 
improved DCM patients who have undergone reverse remodelling, even when LVEF 
is normal.97 In the current study the difference in GLS between cases and controls did 
not reach statistical signifi cance.
The time sequence of contraction and relaxation was disturbed with cases having in-
creased MPI compared with controls. Reduced long-axis function and increased MPI 
are both known to be negative prognostic signs.98, 99 These fi ndings are both parts of 
the pathophysiology of diastolic dysfunction.100 We did not see any difference in con-
tractile reserve in cases vs controls. To our knowledge no studies have examined con-
tractile reserve using bicycle exercise stress test in PPCM. At least two dobutamine 
stress echo studies exist in which contractile reserve at initial presentation did not 
predict LV recovery at 4.7 to 6 months’ follow-up.101, 102 In paper IV post exercise BP 
was higher in cases, and we know LVEF is afterload dependant. Cases also had lower 
HR during physical exercise, but the HR between cases on and off -blocker treat-
ment was similar, rather indicating the difference in  HR may have been attributable to 
chronotropic incompetence secondary to LV dysfunction.103 Interestingly supposedly 
recovered patients where medication had been discontinued seemed, to some extent, 
to have under gone reverse remodelling with near normal cardiac macro-anatomic 
structure, but still had signifi cant reduced cardiac function with residual impaired LV 
and arterial compliance which is a novel fi nding in this population.
Vascular and cardiac changes in PPCM
Only paper IV dealt specifi cally with vascular changes in PPPM. We know that sympa-
thetic stimulation through various mechanisms increases arterial stiffness.104,105 Physi-
cal exercise involves increased sympathetic activation, which persists after exercise. 
Yet nitric oxide and prostaglandin mediated AIx decreases106 occur in the arm and leg 
during, and up to 15 minutes after exercise in healthy subjects.107, 108 Post-exercise 
sympathetic nerve activity is more pronounced in HF patients, but the peripheral re-
sistance can be reduced to that of normal controls with exercise induced precondition-
ing.109 AIx has also been shown to be inversely correlated with heart rate, i.e. each 10 
bpm increase is associated with 4% decrease in AIx.106 In the present data HR at rest 
and post-stress did not differ signifi cantly. Hence ∆AIx from rest to post-stress, in both 
PPCM cases and controls, did not differ signifi cantly, indicating that the vasodilatory 
response was not substantially different between the two groups. Both PWV and AIx 
were higher in the PPCM group post-exercise suggesting structural arterial change 
caused this difference as confi rmed in a recent study.110 There is an inverse relation-
ship between diastolic function and arterial stiffness in healthy men and women,111 
which suggests that structural changes extend through the entire arterial system. Fur-
ther supporting this, is the fact that PWV, mainly determined by aortic stiffness, and 
not endothelial vasodilatory action was signifi cantly higher in PPCM patients at rest. 
Patients perceived to be recovered with normalized LVEF and low levels of symp-
toms where medication had been tapered off and discontinued completely, remarkably 
showed reduced longitudinal septal velocities at par with the medicated cases almost 
fi ve years after diagnosis. Thus AIx and PWV post exercise were similar in cases on 
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and off medication which indicate residual reduced arterial on exertion in supposedly 
recovered cases. No studies have examined arterial stiffness in PPCM, but studies on 
dilated cardiomyopathy indicate an inverse relation between arterial compliance and 
LV stiffness, remodelling and myocardial fi brosis.112
Pharmacological management in PPCM
Paper III allowed us the unique opportunity to monitor the pharmacological manage-
ment of PPCM in a clinical cohort with almost 5 years follow-up. Pillarisetti et al. 
reported that 82% and 85% of PPCM patients received -blockers and ACE-Is/ARBs, 
respectively.113 Haghikia et al. also found that standard treatment with -blockers, 
ACE-Is/ARBs, and bromocriptine was associated with better outcomes in a German 
cohort.26 All patients in the present population received -blockers and ACE-Is/ARBs 
for a mean duration of 20 and 30 months with complete termination of the treatment 
in 16 patients at 1.7 and 2.7 years, respectively. MRAs were initiated in less than half 
of the patients, mainly because of symptomatic hypotension. Previous fi ndings related 
to the duration of HF medication are confl icting. One study reported no deterioration 
in the LVEF after discontinuation of medication,29 whereas Goland et al, pharmaco-
logical treatment notwithstanding, recommend annual follow-up with TTE despite 
complete LV recovery.21 In paper III, only one woman experienced decreased LVEF 
after a primary care physician discontinued her medication. However, in the entire 
cohort, HF medication was successfully discontinued less than 2 years postpartum in 
two-thirds of the patients without any adverse events at the time of the review. 
Strengths and limitations
The completeness of the data in paper I and II, and the detailed information in paper 
III and IV present the greatest strengths in the thesis. Paper I, which characterised HF 
in young patients in all of Sweden, had several advantages such as an unselected and 
large population comprising data from the entire nation, and near-complete follow-up 
in a 20-year period. 
The fi rst population based data in a PPCM cohort, a case-control design with age-
matched controls and a 24 year near-complete follow-up. Unlike the IPR and CDR, 
the MBR contains unique data, including important biological variables. 
In paper III we provided a detailed account of clinical data from early pregnancy 
including natriuretic peptide levels and serial 2D-echo recordings. It also provided 
valuable information about the pharmacological management of PPCM up to more 
than 2½ years postpartum. 
Paper IV retrieved data from the same cohort. This case-control study had several 
strengths such as detailed echocardiographic data including the fi rst data on diastolic 
function and arterial compliance in women with PPCM. 
There were, however also limitations, of which methodological restraints were most 
important. In paper I we used discharge diagnosis codes which posed a risk of under-
estimation.114 Further, hospital admission rates and not true incidence were employed. 
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It is reasonable to believe that young patients with new onset HF undergo comprehen-
sive assessment, including echocardiography in a cardiac ward where the validity of 
the HF diagnosis is higher than stated by Ingelsson et al in their study of elderly men.59 
Additionally the lack of further mortality reduction over the last period would not 
indicate a spurious infl ation in incidence because of inclusion of milder cases. Coding 
practices may certainly have infl uenced the data, but if so most likely at all ages. 
Diagnosing practices for cardiomyopathy changed in the mid-1990s.115 Accordingly, 
the group classifi ed as other, could have harboured undiagnosed cases of cardiomy-
opathy from earlier periods. Unpublished data from an on-going validation study by 
our group, showed that a diagnosis of DCM from 1989 to 2009 could be confi rmed in 
86% of cases (n = 219), importantly with no change in diagnostic accuracy over time. 
A systematic and variable underreporting of hypertension, a major cause of HF, was 
probably present, but this is unlikely to have infl uenced hospitalisation rates differ-
entially in different age groups. The stagnating mortality reduction observed does not 
support a falsely infl ated incidence rate in the young. Thus, potential drifts in diagno-
ses and classifi cations are unlikely to explain the opposing trends in HF incidence in 
younger and older patients.  
The lack of important biological variables, increasingly used over the period, such as 
measurement of natriuretic peptides, or ejection fraction was an important defi ciency. 
The absence of such objective measurements obviously detracts from the compara-
bility of HF rates over time. Heart failure is, however, largely a clinical diagnosis, 
and though we contend that the lack of biological variables is unlikely to explain the 
diverging changes in HF incidence over time in the different age groups, we acknowl-
edge that their addition would have added value to the study. 
In paper II the lack of echocardiography data was arguably more problematic as con-
fi rming the PPCM diagnosis only using ICD-9 and -10 coding proved diffi cult. This 
inherent weakness intrinsic to many registers, was particular important here as LVEF 
<45% is part of the defi nition of PPCM. Of the 272 cases, only just over a quarter of 
cases (n=71) had a PPCM code, but of these only 14 had the ambiguous ICD-9 code, 
674W additionally coding for uterine involution and hepato-renal syndrome. These 
cases were not included unless other data supporting HF in the registers were found. 
The remaining 201 cases were identifi ed by linking the index pregnancy to the fi rst 
occurring HF diagnosis and meticulously excluding all patients with pre-existing con-
ditions including ACHD, IHD, cancers, and pre-existing HF. IPR data has only been 
validated up to 2001, however our own unpublished data do not indicate any decreas-
ing validity of the register towards the end of the study period. 
PPCM patients were almost invariably assessed at departments of internal medicine 
or cardiology where the validity of the HF diagnosis code is known to be high in 
the elderly, and possibly more so among the young and pregnant.59 In our view the 
risk of underestimating the true incidence of PPCM appears more likely, as the data 
from paper III indicate that cases who present with mild or transient symptoms, often 
experience speedy recovery and diagnosis may be missed as symptoms resolve fully 
without them seeking care. 
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Finally, as shown in paper II, when compared with large US register studies based on 
private healthcare delivery and systems that are subject to selection, IPR and MBR 
comprise >3 million unselected delivery diagnoses – which was virtually all deliv-
eries in an entire country in a 24-year period - irrespective of medical coverage or 
socioeconomic status.20, 22, 27, 28
In paper III we only evaluated PPCM retrospectively, which deprived us the chance to 
perform interventions and increased the risk of selection bias as mild cases may have 
gone unnoticed. Missing data from the medical records represented another weakness, 
jeopardizing the validity of most notably the symptoms, the mode and duration of 
pharmacological treatment, and data related to smoking and drug abuse. 
Paper III and IV had two weaknesses in common: small sample sizes and disparate 
examination times. The former limited the statistical power, which may have led to 
an underestimation of the clinical signifi cance of important parameters. The average 
time of the review postpartum varied greatly, as did the collection times of blood tests, 
clinical data, and echocardiographic measurements, complicating the comparisons. 
Thus patients with an early follow-up tended to be on medication whereas patients 
who were reviewed at a later stage had often recovered and were off medication. This 
was also the case in paper IV where most cases were examined within 2012 -2013, but 
investigations were carried out at disparate times after diagnosis which compromised 
the uniformity of the group, but also allowed for ample comparison between early 
medicated vs late recovered cases. Thus the patients who were still on medication at 
follow-up, were on average reviewed 2.9 years sooner after diagnosis than those off 








n = 22 
Controls
n = 15 P*
Mean FU, years after diagnosis, 1.7 (1.45) 4.6 (1.8) 3.0 (2.2) 6.3 (3.8)§ 0.004
Diagnosis, days after delivery 16.3 (27.3) 5.3 (7.7) 11.3 (21.1) NA NA
Maternal age, years 35.1 (4.8) 39.9 (4.3) 37.3 (5.1) 38.1 (3.0) 0.67
BMI, kg/m2 28.7 (5.3) 24.8 (3.5) 26.9 (4.9) 24.0 (4.3) 0.11
Breastfed ?1 week, n (%) 9 (75) 6 (60) 15 (68) NA NA
Breastfeeding, weeks 5.0 (9.0) 9.9 (15.8) 7.2 (12.5) NA NA
NYHA class I, n (%) 10 (84.3) 8 (80) 18 (81) 15 (100) 0.13
NYHA class II-IV, n (%) 2 (16.7) 2 (20) 4 (19) 0 0.13
QRS-width, ms 88 (10) 86 (7) 87 (9.0)‡ 81.3 (6.6) 0.05
All values are mean (SD) unless otherwise stated; FU, follow-up; BMI, Body mass index; *P for controls vs. all 
cases; §years after last delivery; †no data available - normal range given; ‡ missing n=2. 
Table 7. Characteristics of PPCM cases, on and off medication - and healthy controls
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The lack of an exercise induced difference in LVEF between cases and controls in 
paper IV could be due to few participants, or the fact that LVEF is a parameter depen-
dent of both pre- and afterload.116 More likely, however, images at rest were acquired 
with the patient supine, whereas the exercise data were collected with the patient in an 
inclined position and tachypnoic, compromising image quality. In such instances the 




HF among young adults appears to be on the rise. PPCM in particular is poorly de-
scribed on the European continent. These data suggest that increasing incidence of 
both PPCM and other cardiomyopathies are taking place. Whether this is due to true 
demographic changes including rising obesity and increased levels of immigration 
from countries with higher incidences; or can indeed be ascribed to methodological 
reasons like improved case ascertainment, could not be conclusively discerned. Mor-
tality in young patients with HF decreased drastically up to the turn of the millennium. 
PPCM is rare in Europe and constitutes a unique entity among the cardiomyopathies 
as long-term prognosis in PPCM appears to be better than in all other types of id-
iopathic cardiomyopathies. Prognosis in these Swedish data is comparable to data 
from Germany and USA, but more favourable than data from outside the West. Even 
though long-term mortality in PPCM was low, PPCM was still associated with more 
than 20-fold increased risk of death compared with controls, with most deaths occur-
ring within 3 years of diagnosis. 
Clinically PPCM often presents dramatically. However, early diagnosis and timely 
management may improve prognosis. Medication was successfully initiated and ta-
pered in 2/3 of PPCM patients with no known adverse effects after almost fi ve years. 
As seen in most cohorts, and even in this population, preeclampsia was strongly 
linked to PPCM, but it was inversely associated with late recovery and mortality in 
concomitant PPCM. 
Echocardiographic assessment revealed that LV size, but not LVEF predicted symp-
tomatic recovery in PPCM at 1 year. The NT-proBNP level at presentation was a good 
marker of disease and was elevated in all patients, but bore no correlation with long-
term recovery. 
Reduced compliance of the left ventricle and the arterial vasculature in PPCM patients 
was present up to almost fi ve years after diagnosis irrespective of whether the patients 
were clinically recovered or still under medication. 
Specifi c conclusion
  •  Our fi ndings indicate HF admissions in young adults continue to increase despite 
decreasing HF hospitalisation in older adults since the mid-90s.
  •  Mortality rates in HF in the young have more than halved since the 80s, but with a 
stagnating trend.
  •  Cardiomyopathy diagnoses at least doubled in all age groups between 1987 and 
2006.
45
  •  PPCM is relatively rare in Sweden (approximately 1 in 9200), but the incidence 
appears to be on the rise.
  •  Data from the entire country show that obesity, multi-fetal pregnancies, non-OECD 
country origin are associated with PPCM.
  •  Mortality (mean follow-up 16.4 years) in PPCM patients is more than 20 times that 
of healthy controls.
  • More than two-thirds of PPCM deaths occur within 3 years after diagnosis.
  • Concomitant preeclampsia in PPCM appears to be linked to a better outcomes. 
  •  We only identifi ed LV size at presentation as predictor for one-year outcome in 
PPCM.
  •  NT-proBNP was elevated in all patients with PPCM but was not related to long-
term prognosis, but rather to high blood pressure, preeclampsia and the severity of 
symptoms at presentation.
  •  Residual increased blood pressure, pulse wave velocity and augmentation index 
was shown in cases off medication up to almost fi ve years after diagnosis. 
  •  Despite normalized cardiac structures and LVEF, arterial stiffness persists years 
after the diagnosis of PPCM.
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FUTURE PERSPECTIVES
HF is increasingly being recognized in young age as more physicians are cognizant of 
the economic burden on the healthcare systems and the fi nancial and emotional strain 
it can put on the families in question. The declining case fatality reduction with lack of 
further improvement after 2001 is a cause for concern and despite the recent progress 
with the addition of the angiotensin-neprilysin agents (the so-called ARNEs),117 new 
ways other than renin-angiotensin system inhibition should be sought after. 
PPCM, a condition which at early presentation mimics physiological pregnancy, re-
quires early detection. To achieve this, tools for identifying sentinel signs of endo-
thelial and vessel disease may be of value. Large prospective studies are needed to 
confi rm these fi ndings. Of particular utility would be to confi rm if weight control in 
early pregnancy and closer monitoring of preeclamptic mothers at diagnosis would 
be cost-benefi cial in avoiding the development of PPCM. Also future studies should 
focus on to what extent genetic or environmental factors account for the excess inci-
dence and mortality in women of sub-Saharan African descent.
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SAMMANFATTNING PÅ SVENSKA
Hjärtsvikt (HF) drabbar tusentals svenskar varje år, men den samlade förekomsten 
av nydiagnosticerade fall har minskat sedan mitten på 90-talet. Huruvida detta också 
gäller unga med hjärtsvikt har inte fastställts. Inte heller vet man mycket om dödlig-
heten och karaktären av hjärtsvikt hos unga. Vi ville  klarlägga detta genom  studier 
av Patientregistret och Dödsorsaksregistret  av alla hjärtsviktinläggningar bland unga 
vuxna yngre än 55 år i Sverige mellan 1987-2006. 
Peripartum kardiomyopati (PPCM) är hjärtsvikt under slutet av graviditeten eller un-
der barnsängstiden utan känd orsak. Ämnet har studerats vid en del säten framfö-
rallt i USA, Sydafrika och Haiti, men senare också i Tyskland, men aldrig i Sverige. 
Vid genomgång av alla graviditetsrelaterade hjärtsviktsfall i Sverige från 1987–2010 
syftade vi till att identifi era: omfattningen och dödligheten av PPCM i hela Sverige 
och vilka patientkarakteristika som är förknippade med tillståndet. Vi hade ytterligare 
förmånen att kunna genomföra klinisk uppföljning och journalgenomgång på 24 kvin-
nor med PPCM och ytterligare utföra hjärtultraljudsundersökningar i vila och under 
arbete samt bestämma artärstyvhet hos 22 kvinnor med PPCM diagnos och jämföra 
dessa med 15 friska mödrar.
Första delarbetet visade att HF hos unga vuxna fortsätter att öka trots minskande HF 
inläggningar hos äldre sedan mitten av 90-talet. Dödligheten i HF hos unga har mer än 
halverats sedan slutet på 80-talet, men med en stagnerande trend. Kardiomyopatidi-
agnosen ställdes minst dubbelt så ofta i slutet av undersökningsperioden (1987-2006) 
som i början.
I andra delarbetet där vi hittade 272 kvinnor med PPCM i hela Sverige såg vi att till-
ståndet är relativt ovanligt (1 på 9200 födslar) i Sverige, men förekomsten verkar vara 
på uppgång (1 på 4500 födslar i slutet av perioden). Data från hela landet visar också 
att fetma, tvilling/trillinggraviditeter och att vara född i ett icke-OECD-land alla är 
förknippade med ökad förekomst av PPCM. Dödligheten bland PPCM-patienter var 
mer än 20 gånger så hög som hos friska kontroller, och mer än två tredjedelar av dessa 
dödsfall inträffade inom 3 år efter diagnos. Samtidig preeklampsi hos dessa kvinnor 
verkade vara kopplad till en bättre prognos.
Hos 24 kvinnor med ultraljudsverifi erad PPCM identifi erades endast vänsterkammar-
storlek som prediktor för gynnsamt utfall vid ett års uppföljning. Nivåerna av natriu-
retiska peptider som indikerar kraftig tänjning i hjärtkamrarna var förhöjda i samtliga 
patienter med PPCM, men var inte relaterade till långtidsprognosen, utan snarare till 
högt blodtryck och svåra symtom vid insjuknadet.
I sista delarbetet, där vi fokuserade på hjärtultraljudsfynd och icke-invasiva artärstyv-
hetsmätningar hos 22 PPCM-fall, sågs förhöjt blodtryck och ökad pulsvågshastighet 
i artärerna hos patienterna jämfört med friska kontroller, i upp till nästan fem år efter 
diagnos, oavsett om patienterna hade trappats ur medicinering och därmed friskför-
klarats eller inte. Således kvarstår artärstyvhet hos kvinnor med PPCM lång tid efter 
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